GENOR-B (06998) Proposes to Increase Authorized Share Capital to $60,000

Stock News2025-12-22

GENOR-B (06998) announced that, as shareholders approved the resolution to change the company's name during the Extraordinary General Meeting, the conditions for the proposed name change have been fulfilled as of the date of this announcement. Accordingly, effective from the merger time (9:00 AM Hong Kong Time on December 30, 2025, as disclosed in the circular), the company's English name will change from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited," while its dual foreign-language Chinese name will change from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司."

Additionally, shareholders approved the resolution to increase the authorized share capital during the same meeting. The company's authorized share capital has been raised from $20,000 (divided into 1 billion shares with a par value of $0.00002 each) to $60,000 (divided into 3 billion shares with a par value of $0.00002 each). The newly issued shares will rank equally with the existing shares in all respects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment